Soligenix Inc. buy melinda
Start price
30.08.18
/
50%
€20.54
Target price
01.10.18
€32.44
Performance (%)
20.39%
End price
01.10.18
€24.74
Summary
This prediction ended on 01.10.18 with a price of €24.74. The BUY prediction by melinda finished with a performance of 20.39%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Soligenix Inc. | - | - | - | - |
| iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
| iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
| iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
| iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by melinda for this prediction
In the thread Soligenix Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 27/09 | 15:00 Assemblée générale
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease.
It operates through the BioTherapeutics, and Vaccines/BioDefense segments.
The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma.
The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate.
The company was founded in 1987 and is headquartered Princeton, NJ.
Nombre d'employés : 18 personnes.